AASLD 2025

Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.

Download all

AASLD 2025 - Clinical

Title	Description	Download
Two-year time course of biomarker and imaging responses in well-compensated MASH cirrhosis patients treated with resmetirom	Oral Presentation	Download Preview
Improvement in health-related quality of life in non-cirrhotic and cirrhotic patients with metabolic dysfunction-associated steatotic liver disease treated with Resmetirom: Data from MAESTRO NAFLD	Oral Presentation	Download Preview
Durability of Resmetirom Response in MASLD Patients After Two Years of Treatment in MAESTRO-NAFLD-OLE	Poster Presentation	Download Preview
Comparison of MAESTRO-NASH and ESSENCE: effects of resmetirom and semaglutide relative to placebo on primary and secondary liver biopsy endpoints using aligned endpoints and statistical methods	Poster Presentation	Download Preview
Analysis of biomarkers PRO-C3 and ELF components in baseline MASH-MASLD and MASH cirrhosis patients; correlations between change in PRO-C3 and ELF in resmetirom-treated patients from the MAESTRO-NASH trial	Poster Presentation	Download Preview

Download all

AASLD 2025 - HEOR

Title	Description	Download
Semaglutide Use Among Individuals Diagnosed with Metabolic-dysfunction Associated Steatotic Liver Disease in a Medicare Advantage Program	Poster Presentation	Download Preview
Semaglutide Titration Patterns Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Poster Presentation	Download Preview
Semaglutide Discontinuation Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Poster Presentation	Download Preview
Role of metabolic dysfunction-associated steatohepatitis (MASH) as a risk factor for hepatocellular carcinoma (HCC) development	Poster Presentation	Download Preview
Patient characteristics and treatment patterns among patients using resmetirom in the real-world setting	Poster Presentation	Download Preview
Evaluating the early real-world impact of resmetirom in patients with metabolic dysfunction-associated steatohepatitis (MASH): A United States cohort study using electronic medical records	Poster Presentation	Download Preview
Characterizing Healthcare Costs in Medicare Beneficiaries with a New Diagnosis of Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis	Poster Presentation	Download Preview
Characterizing Healthcare Costs in Medicare Beneficiaries with a New Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensated Cirrhosis	Poster Presentation	Download Preview
An Innovative Screening and Treatment Pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease: The UK-CURES Approach	Poster Presentation	Download Preview